Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15126 - 15150 of 15772 in total
Autologous pancreatic islet therapy involves isolating the patient's own insulin-producing cells.
Investigational
Investigational
SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer modified alginate spheres
Investigational
OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells.
Investigational
PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme.
Investigational
ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Investigational
ST266 is an amniotic membrane-derived cellular cytokine solution.
Investigational
VGB-R04 is an adeno-associated viral vector delivering human FIX Padua gene.
Investigational
MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.
Investigational
Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.
Investigational
Investigational
RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational
SHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With Advanced Solid Cancer).
Investigational
BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Investigational
Investigational
Empasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.
Investigational
Investigational
Visugromab is under investigation in clinical trial NCT06059547 (Neoadjuvant Immunotherapy in Combination With the Anti-gdf-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer).
Investigational
Rilvegostomig is under investigation in clinical trial NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (Artemide-biliary01)).
Investigational
Remternetug is under investigation in clinical trial NCT05463731 (A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)).
Investigational
Plozasiran is under investigation in clinical trial NCT05089084 (Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)).
Investigational
Lunsekimig is under investigation in clinical trial NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma).
Investigational
Lepunafusp alfa is under investigation in clinical trial NCT04453085 (An Extension Study of JR-171-101 Study in Patients With MPS I).
Investigational
Forimtamig is under investigation in clinical trial NCT06055075 (A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma).
Investigational
Matched Description: … Forimtamig is under investigation in clinical trial NCT06055075 (A Study Evaluating Safety, Tolerability, and
Displaying drugs 15126 - 15150 of 15772 in total